Lipocine Inc. Q3 FY25 Results

Summary

Lipocine Inc. announced its financial results for the third quarter ended September 30, 2025. The company reported a net loss of $3.2 million, or ($0.59) per diluted share, compared to a net loss of $2.2 million in the same quarter of the previous year. Royalty revenue from TLANDO sales was $115,000. As of September 30, 2025, Lipocine had $15.1 million in unrestricted cash, cash equivalents, and marketable investment securities. For the nine months ended September 30, 2025, the company reported a net loss of $7.3 million and revenue of $831,000.

Key Highlights

1. 1

   Lipocine had $15.1 million of unrestricted cash, cash equivalents and marketable investment securities as of September 30, 2025.

2. 2

   The company reported a net loss of $3.2 million, or ($0.59) per diluted share, for the quarter ended September 30, 2025.

3. 3

   Royalty revenue from TLANDO sales was $115,000 during the quarter ended September 30, 2025.

4. 4

   Research and development expenses increased to $2.7 million for the quarter ended September 30, 2025, compared to $1.6 million in 2024.

5. 5

   For the nine months ended September 30, 2025, Lipocine reported a net loss of $7.3 million, or ($1.35) per diluted share.

6. 6

   Lipocine recognized revenue of $831,000 for the nine months ended September 30, 2025, compared to $7.7 million in 2024.